Mankind Pharma Limited (MANKIND)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 15 July 2026

₹2,531.1 ↓ 4.52% (1Y)

🎯 Key Takeaways

Mankind Pharma is transitioning from a diversified healthcare player to a focused pharmaceutical growth company, marked by the divestment of its non-core Broadway Hospitality Services and the creation of a Netherlands subsidiary to centralize R&D investments. This strategic shift underscores a deliberate move to enhance operational focus on core pharma while building infrastructure for future innovation.
Revenue grew 5% QoQ to ₹3,230 in Q3FY25.
⚠️ Regulatory and supply chain volatility remain material risks, as highlighted in the annual report, potentially affecting raw material sourcing and man

Market Cap

₹1.03 L Cr

P/E Ratio

49.2

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About MANKIND 📊 Interactive Charts

📖 The Story

Mankind Pharma is transitioning from a diversified healthcare player to a focused pharmaceutical growth company, marked by the divestment of its non-core Broadway Hospitality Services and the creation of a Netherlands subsidiary to centralize R&D investments. This strategic shift underscores a deliberate move to enhance operational focus on core pharma while building infrastructure for future innovation. The company demonstrated strong financial momentum in FY2026 with 17% YoY revenue growth and robust profitability, supporting its expansion ambitions in chronic therapies and digital transformation.

📰 What's Happening

The board approved the divestment of Broadway Hospitality Services for ₹49 crores to AKRK Projects LLP, a non-promoter buyer, with completion expected within 90 days, generating immediate cash inflow. Concurrently, a Netherlands subsidiary was incorporated to hold up to €5 million in phased R&D investments for niche therapy development, signaling a strategic pivot toward innovation. This dual action — monetizing non-core assets while building R&D capacity — reflects management’s intent to streamline operations and reinvest proceeds into high-growth areas of the pharmaceutical business.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	2,053	2,579	2,708	2,607	2,441	2,893	3,077	3,230
Operating Profit	464	713	743	677	683	782	959	907
OPM %	20.3%	25.4%	25.2%	23.3%	24.2%	23.6%	27.6%	25.7%
Net Profit	294	494	511	460	477	543	659	385
EPS	₹7.13	₹12.15	₹12.51	₹11.33	₹11.76	₹13.39	₹16.31	₹9.45

Revenue has grown steadily from ₹2,053 crores in Q4FY23 to ₹3,230 crores in Q3FY25, reflecting consistent top-line expansion, while operating margins have stabilized around 25-27% despite minor fluctuations. Net profit peaked at ₹659 crores in Q2FY25 before moderating to ₹385 crores in Q3FY25, indicating a strategic shift from short-term profitability to reinvestment phase. EPS declined from ₹16.31 in Q2FY25 to ₹9.45 in Q3FY25, aligning with increased investments and potential one-time costs related to restructuring or R&D setup, though full-year FY2026 profitability remains strong at ₹1,938 crores PAT.

🔮 Management Outlook & What's Next

Management emphasized expansion in chronic therapies, digital transformation, and ESG initiatives during the FY2026 annual report, targeting 50% chronic therapy share in the medium term and 100% renewable energy use by FY2030. The reappointment of Satish Kumar Sharma as Whole Time Director signals continuity in leadership, while the AGM will review strategic progress on these fronts. The establishment of the Netherlands R&D vehicle and focus on niche therapies indicate forward-looking investments aimed at sustaining long-term growth beyond current product lines.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

Regulatory and supply chain volatility remain material risks, as highlighted in the annual report, potentially affecting raw material sourcing and manufacturing continuity. Foreign exchange fluctuations could impact international R&D investments and financial planning, especially with the new Dutch entity. Additionally, the transition to chronic therapy focus may face execution risks if market adoption or competitive pressures are underestimated, requiring sustained innovation and commercial scalability.

📋 Recent Filings

🧠 Analyst's Read

Mankind Pharma is repositioning for long-term growth through strategic divestments and R&D investments, supported by strong underlying financial performance and strategic clarity. Investors should monitor the successful closure of the Broadway sale, progress on R&D milestones from the Netherlands entity, and execution of chronic therapy expansion plans, as these will be critical to sustaining momentum beyond the current transition phase.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on MANKIND

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when MANKIND files new disclosures

Track MANKIND filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MANKIND — Free

Free account · 2 AI queries/day